Literature DB >> 33673104

Tumor Heterogeneity in Glioblastomas: From Light Microscopy to Molecular Pathology.

Aline P Becker1, Blake E Sells2, S Jaharul Haque1, Arnab Chakravarti1.   

Abstract

One of the main reasons for the aggressive behavior of glioblastoma (GBM) is its intrinsic intra-tumor heterogeneity, characterized by the presence of clonal and subclonal differentiated tumor cell populations, glioma stem cells, and components of the tumor microenvironment, which affect multiple hallmark cellular functions in cancer. "Tumor Heterogeneity" usually encompasses both inter-tumor heterogeneity (population-level differences); and intra-tumor heterogeneity (differences within individual tumors). Tumor heterogeneity may be assessed in a single time point (spatial heterogeneity) or along the clinical evolution of GBM (longitudinal heterogeneity). Molecular methods may detect clonal and subclonal alterations to describe tumor evolution, even when samples from multiple areas are collected in the same time point (spatial-temporal heterogeneity). In GBM, although the inter-tumor mutational landscape is relatively homogeneous, intra-tumor heterogeneity is a striking feature of this tumor. In this review, we will address briefly the inter-tumor heterogeneity of the CNS tumors that yielded the current glioma classification. Next, we will take a deeper dive in the intra-tumor heterogeneity of GBMs, which directly affects prognosis and response to treatment. Our approach aims to follow technological developments, allowing for characterization of intra-tumor heterogeneity, beginning with differences on histomorphology of GBM and ending with molecular alterations observed at single-cell level.

Entities:  

Keywords:  glioblastoma; glioma; neoplastic stem cells; precision medicine; prognosis; review; tumor heterogeneity; tumor microenvironment

Year:  2021        PMID: 33673104     DOI: 10.3390/cancers13040761

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  14 in total

1.  Brain Distribution of Berzosertib: An Ataxia Telangiectasia and Rad3-Related Protein Inhibitor for the Treatment of Glioblastoma.

Authors:  Surabhi Talele; Wenjuan Zhang; Danielle M Burgenske; Minjee Kim; Afroz S Mohammad; Sonja Dragojevic; Shiv K Gupta; Ranjit S Bindra; Jann N Sarkaria; William F Elmquist
Journal:  J Pharmacol Exp Ther       Date:  2021-09-23       Impact factor: 4.402

2.  Tracing the origins of glioblastoma by investigating the role of gliogenic and related neurogenic genes/signaling pathways in GBM development: a systematic review.

Authors:  Ovais Shafi; Ghazia Siddiqui
Journal:  World J Surg Oncol       Date:  2022-05-10       Impact factor: 3.253

3.  A novel therapeutic strategy of multimodal nanoconjugates for state-of-the-art brain tumor phototherapy.

Authors:  Hyung Shik Kim; Minwook Seo; Tae-Eun Park; Dong Yun Lee
Journal:  J Nanobiotechnology       Date:  2022-01-04       Impact factor: 10.435

Review 4.  Recent Development in NKT-Based Immunotherapy of Glioblastoma: From Bench to Bedside.

Authors:  Yutao Li; Amit Sharma; Jarek Maciaczyk; Ingo G H Schmidt-Wolf
Journal:  Int J Mol Sci       Date:  2022-01-24       Impact factor: 5.923

5.  Alteration of the translational readthrough isoform AQP4ex induces redistribution and downregulation of AQP4 in human glioblastoma.

Authors:  Onofrio Valente; Raffaella Messina; Giuseppe Ingravallo; Emilio Bellitti; Domenico Sergio Zimatore; Luigi de Gennaro; Pasqua Abbrescia; Roberta Pati; Claudia Palazzo; Grazia Paola Nicchia; Maria Trojano; Francesco Signorelli; Antonio Frigeri
Journal:  Cell Mol Life Sci       Date:  2022-02-20       Impact factor: 9.207

6.  Increased Ascorbate Content of Glioblastoma Is Associated With a Suppressed Hypoxic Response and Improved Patient Survival.

Authors:  Eleanor R Burgess; Rebekah L I Crake; Elisabeth Phillips; Helen R Morrin; Janice A Royds; Tania L Slatter; George A R Wiggins; Margreet C M Vissers; Bridget A Robinson; Gabi U Dachs
Journal:  Front Oncol       Date:  2022-03-28       Impact factor: 6.244

7.  Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trial.

Authors:  Corinne E Griguer; Claudia R Oliva; Christopher S Coffey; Merit E Cudkowicz; Robin A Conwit; Anna L Gudjonsdottir; Dixie J Ecklund; Janel K Fedler; Tina M Neill-Hudson; Louis B Nabors; Melanie Benge; James R Hackney; Marianne Chase; Timothy P Leonard; Toral Patel; Howard Colman; Macarena de la Fuente; Rekha Chaudhary; Karen Marder; Teri Kreisl; Nimish Mohile; Milan G Chheda; Katharine McNeill; Priya Kumthekar; Aclan Dogan; Jan Drappatz; Vinay Puduvalli; Agnes Kowalska; Jerome Graber; Elizabeth Gerstner; Stephen Clark; Michael Salacz; James Markert
Journal:  Neurooncol Adv       Date:  2021-12-24

Review 8.  Current Opportunities for Targeting Dysregulated Neurodevelopmental Signaling Pathways in Glioblastoma.

Authors:  Danijela Drakulic; Marija Schwirtlich; Isidora Petrovic; Marija Mojsin; Milena Milivojevic; Natasa Kovacevic-Grujicic; Milena Stevanovic
Journal:  Cells       Date:  2022-08-15       Impact factor: 7.666

9.  Mesenchymal and Proneural Subtypes of Glioblastoma Disclose Branching Based on GSC Associated Signature.

Authors:  Giedrius Steponaitis; Arimantas Tamasauskas
Journal:  Int J Mol Sci       Date:  2021-05-07       Impact factor: 5.923

Review 10.  Profiling Cancer Cells by Cell-SELEX: Use of Aptamers for Discovery of Actionable Biomarkers and Therapeutic Applications Thereof.

Authors:  Sarah Shigdar; Lisa Agnello; Monica Fedele; Simona Camorani; Laura Cerchia
Journal:  Pharmaceutics       Date:  2021-12-24       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.